Markets

Acrivon Therapeutics Advances ACR-7280, Showing Complete Tumor Regression In AML Models, With IND Filing Targeted For H1 2027

Oct 20, 2026 · 08:36 AM ET· updated 54m ago

ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft modelsPrioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent activity and strong

Why It Matters

Acrivon's new cancer medicine showed strong results in early lab tests. This is a positive step, but the company won't test it in people until late 2026.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

ACRV1.77

+0.13 (+7.93%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.